Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00736047 | Study to Evaluate the Efficacy, Safety, Tolerability and Immunogenicity of 100µg NIC002 Vaccine in Cigarette Smokers Who Are Motivated to Quit Smoking. | PHASE2 | COMPLETED | 200 | — | — | Aug 1, 2008 | Oct 1, 2009 | Mar 21, 2017 | 2 | Germany |
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | - |
| 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| NIC002 | BIOLOGICAL | - |
| Placebo | BIOLOGICAL | - |
Inclusion Criteria: * Healthy male and female smoking subjects age 18 to 65 years of age * Subjects must be smoking 10 or more cigarettes per day during the past 12 months * The exhaled breath carbon monoxide (CO) concentration must be 10 ppm or more at screening. Urine cotinine at screening must b...